New therapeutic agents are needed to overcome the toxicity and suboptimal efficacy observed in current treatment of glomerulonephritis (GN). BaxB01 is a fully human monoclonal antibody targeting a disease-related immunologically distinct isoform of Macrophage migration Inhibitory Factor (MIF), designated oxidized MIF (oxMIF) and locally expressed in inflammatory conditions. We report the pharmacokinetic profile of BaxB01, and its dose and exposure-related disease-modifying activity in experimentally induced rat GN.
Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis Werner Höllriegl a 
Introduction
Crescentic glomerulonephritis (GN) presents with anti-glomerular basement membrane (GBM) antibodies or immune complexes deposited in glomeruli, but also pauci-immune without deposits of immunoglobulins or complement in glomeruli, and is a major cause of rapidly progressive renal failure and severe glomerulosclerosis (Tam et al., 1999) , and is associated with activation of complement and Fc receptors and recruitment and infiltration of leukocytes in particular Tcells, neutrophils and monocytes (Kurts et al., 2013) . These cells are a major constituent of the crescentic lesions and persist locally within the inflammatory site producing cytokines that propagate inflammatory tissue damage and rapidly progressive nephritis (Peterson and Winchester, 2005) .
Conventional immunosuppressive therapy of inflammatory kidney disease is associated with considerable toxic effects and suboptimal efficacy. Therefore, new therapeutic agents that overcome these issues are needed, and biologic agents offer exciting opportunities (Smith et al., 2010) . While current treatment induces initial remission in many patients, the actual renal relapse rates are still high and favor prolonged immunosuppression (Houssiau, 2012) . Sequelae of inflammatory kidney diseases, such as ANCA-Vasculitis, Goodpasture disease or Lupus nephritis (LN), also encompass a potential for rapid progressive GN and therefore disease management might require attenuation of inflammation to curtail further renal damage and suppression of autoimmunity to prevent exacerbation of disease (Parikh and Rovin, 2016) .
Macrophage Migration Inhibitory Factor (MIF) is a regulatory cytokine of the innate and adaptive immune response and is produced, stored, and secreted by macrophages and other cells of the immune system (Lolis and Bucala, 2003) . MIF is therefore considered a promising and rational therapeutic target across inflammatory conditions (Hoi et al., 2007; Leng et al., 2011; Lang et al., 2015; Bruchfeld et al., 2016) . Anti-MIF treatment has previously been shown to prevent loss of renal function and to inhibit renal leukocyte infiltration and activation in an experimental model of rat GN (Yang et al., 1998) induced by administration of nephrotoxic serum (NTS) . The murine NTS model is dependent on kidney-infiltrating T helper (Th) 17 cells and then followed by infiltrating Th1 cells, which recruit neutrophils and macrophages, respectively, and cause sustained kidney inflammation. In a later phase of disease, regulatory T cells (Tregs) might infiltrate the kidney in an attempt to limit disease activity (Kurts et al., 2013; Artinger et al., 2017) . Nonetheless, the pleiotropic functions and ubiquitous cellular synthesis of MIF by non-immune and immune cells pose conceptual difficulties in developing safe and targeted pharmacological interventions.
BaxB01 is a previously described fully human monoclonal IgG1 antibody (mAb) and has been shown to neutralize the biologic function of MIF (Kerschbaumer et al., 2012) . Furthermore, BaxB01 has been shown to ameliorate inflammatory conditions including GN and to bind with high specificity to oxMIF, a redox dependent and immunologically distinct conformational isoform of MIF, present in the circulation of SLE patients and in the urine of patients with acute LN (Thiele et al., 2015) .
Here, we describe for the first time the pharmacokinetics (PK) of BaxB01 in the rat, and dose-related disease-modifying activity in experimental immune GN. We also deduced minimally effective dose levels and applied pharmacodynamic (PD) modeling to define exposure levels for optimal attenuation of disease progression. The data link posology with anti-inflammatory mechanism and ameliorated glomerular histopathology. Finally, we provide evidence for the safety and tolerability of this novel therapeutic approach in the treatment of inflammatory kidney disease.
Materials and methods

Materials
Recombinant human or rat MIF was produced in Escherichia coli BL21 (Stratagene, La Jolla, CA) and monoclonal anti-oxMIF antibody BaxB01 was produced in Chinese hamster ovary cells and purified as previously described (Kerschbaumer et al., 2012) . Nephrotoxic anti-rat GBM serum (NTS) was prepared by subcutaneous immunization of New Zealand White rabbits with 1 mg of GBM in 1 ml of complete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO); and anti-rat RBC antibodies were absorbed as previously described (Tam et al., 1999) . LAL test results on NTS indicated endotoxin levels < 0.3 EU/ml.
All animal experiments were approved by a local IACUC and conducted in compliance with applicable national laws and regulations in AAALAC accredited facilities.
BAXB01 affinity
BaxB01 or a non-binding control IgG1-antibody was immobilized to Biacore CM5 optical sensor chips (GE Healthcare, Piscataway, NJ) using standard amine coupling conditions. Rat or human recombinant MIF were diluted in HBS-EP buffer (GE Healthcare) to concentrations of 50, 75, 100, or 150 nM in the presence of 0.2% Proclin300 (active component 5-chloro-2-methyl-4-isothiazolin-3-one; Sigma) to transform MIF into an oxMIF surrogate (Thiele M et al., 2015) . Proclin treated MIF was applied to immobilized BaxB01 and affinity measured with a Biacore™ 3000 Instrument (GE Healthcare). The kinetics of the concentration series were analyzed by local simultaneous association/dissociation fitting of each binding curve to the iterative Langmuir 1:1 interaction model with mass transfer compensation provided by the BiaEvaluation software (GE Healthcare).
Rat monocyte cell migration assay
BaxB01 inhibition of random migration of rat monocytes was tested in a Transwell™ Chemotaxis assay (Corning, Tewksbury, MA 01876). Briefly, rat alveolar macrophages ([AgC11×3A, NR8383.1]; ATCC® CRL-2192) were seeded at a density of 10 6 cells/ml in serum-free culture media (F12K; Life Technologies, Carlsbad, CA) in the top chambers of porous Transwell™ inserts (8 µm; Corning, Tewksbury, MA). Cell migration towards BaxB01 (0.04-30 nM) in the lower chamber was determined in five separate experiments using microscopy after 16 h at 37 C. IC50 values were calculated by 4-parameter logistic nonlinear regression of the number of migrated cells normalized to buffer negative control (chemotactic index) using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).
PK analysis in rat plasma
Briefly, sheep anti-human IgG1 (The Binding Site, Birmingham, UK; TBS AU006), diluted (1:500) in 0.1 M carbonate buffer (pH 9.5) was coated to 96-well Maxisorp F96 plates (Nalge Nunc, Rochester, NY) overnight. After a washing step with PBST (phosphate-buffered saline with 0.05% Tween 20), the wells were blocked with PBST with 0.1% gelatin, 2 mM benzamidine, at 37°C for 1 h. Then samples or standards (CRM470 IgG1 calibration curve ranging from 15.7 to 252 ng/ml in five serial dilutions) were loaded in duplicate. After 15 min-incubation at room temperature (RT), affinity-purified sheep anti-human IgG1 antibody peroxidase conjugate (The Binding Site, Birmingham, UK; AP-006) was added and incubated at RT for 1 h. After washing, tetramethylbenzidine substrate SureBlue (KPL, Gaithersburg, MD) was added and the peroxidase reaction stopped with 1.5 M sulfuric acid. Absorbance was determined in an ELISA reader at 450/620 nm. Quantitative evaluation was based on a double-logarithmic calibration curve approach correlating blank-corrected mean optical densities (ODs) of the standard's concentrations with their IgG1 concentrations. This calibration curve was used to calculate IgG1 concentrations of the samples.
Pharmacokinetics (PK) study in healthy and diseased Wistar Kyoto rats
Male Wistar Kyoto (WKY) rats (Charles River, Sulzfeld, Germany) received a single IV bolus injection of BaxB01 (50 mg/kg) and blood samples (0.4 ml) were drawn from the ventral tail artery (batch design, n = 3/time point) three days before and 15 min and 1, 3, 7, 10, and 14 days after administration. Similarly, blood from diseased animals was sampled at designated time points starting four days after disease induction with rabbit NTS (described below). Whole blood was collected and processed as 3.8% trisodium citrated plasma and stored in 100 μL aliquots at ≤ −20°C. To compare PK parameters from healthy and diseased rats, the same nominal dose of BaxB01, rat strain, body weight, and time points were used.
2.6. PK/PD efficacy study in diseased Wistar Kyoto (WYK) rats to 13 treatment groups. To induce GN, NTS was administered as a 1:40 dilution in 0.9% sodium chloride (Baxter, IL) in 1.0 ml via tail vein injection on day 0. Four days after administration of NTS (Suppl. Fig.  S1 ), animals received one IV tail-vein injection of BaxB01 (2 ml/kg) at dose levels of 1, 5, 10, 20, or 40 mg/kg. Selected groups received a second BaxB01 injection on day 11 using identical dose levels. Animals in control groups were administered an IgG1 isotype control antibody (40 mg/kg) or sterile buffer (250 mM glycine, pH 5.0). Rats were euthanized on day 8 or day 15 after disease induction.
Blood sampling for PK analysis was done using a batch design at 0.25, 8, and 72 h, and 2, 48, and 96 h, respectively. The following parameters were calculated grouped by test or control article, dose, and study day: area under the concentration versus time curve (AUC), maximum concentration following infusion (C max ), time to reach C max (T max ), in vivo recovery (IVR), and incremental recovery (IR). Dose proportionality was evaluated, and differences in AUC and C max between the first and second administration assessed.
Urine was collected in metabolic cages over 24 h pre-dosing of NTS, over 24 h before each test or control article administration, and again over 24 h before euthanasia. Blood was collected from n = 4/timepoint before treatment with BaxB01 (or isotype control) and 0. 25, 2, 8, 48, 72 and 96 h thereafter. In repeat dose groups, blood samples were taken immediately before and 0.25, 2, 8, 48, 72 and 96 h after the second administration of BaxB01 (or isotype control). Blood from buffertreated animals was collected only prior to euthanasia. Citrated plasma was stored at −70°C until analyzed for human IgG1 as described above.
Urine analyses
To quantify total protein, albumin and TNF-α, urine samples were diluted and evaluated in duplicate, and levels assessed according to the manufacturer's instructions using commercially available kits. Samples were analyzed with a SpectraMax microplate spectrophotometer and SoftMax Pro software (Molecular Devices, Sunnyvale, CA, USA). Briefly, total protein was determined using Pierce Coomassie Plus (Bradford) Assay Kit (ThermoFisher, Waltham, MA, USA). Samples and serial dilution of the standard (bovine serum albumin) were incubated with Coomassie Plus reagent for 10 min and analyzed at 595 nm. Total protein in samples was calculated based on a 4-parameter standard curve fit. Albumin concentrations in samples were evaluated using Nephrat II Elisa Kit (Exocell Inc., Philadelphia, PA, USA). Samples were incubated together with the antibody-horseradish peroxidase (HRP) conjugate for 30-60 min. Stop solution was applied after 5 min of incubation with TMB substrate and samples analyzed at 450 nm. Albumin concentrations were calculated based on a rat serum albumin standard using a log/log curve fit. TNF-α was measured with the Quantikine Rat TNF-α/TNFSF1A Immunoassay (R&D Systems Inc., Minneapolis, MN, USA). Samples were incubated for 2 h on assay plates followed by 2 h incubation with TNF-α substrate. TNF-α was detected at 450 nm after 30-min incubation with TMB substrate and addition of stop solution. TNF-α concentration was calculated based on a recombinant rat TNF-α standard using a 4-parameter curve fit.
Urinalysis calculations were adjusted to collected volumes as follows: albumin (mg/24 h) = (urine volume[ml] × Alb[mg/dl])/100, total protein (mg/24 h) = (urine volume[ml] × total protein[ug/ml])/ 1000, TNF-α (pg/24 h) = urine volume (ml) × TNF-α (pg/ml).
Tissue collection and histology
Kidney sections were fixed in 10% neutral buffered formalin, trimmed, embedded in paraffin, and stained with hematoxylin and eosin and Periodic acid-Schiff for staining of basement membranes. Immunohistochemical staining was performed after antigen retrieval with an anti-ED-1 antibody (mouse anti-rat CD68, Serotec MCA341R) at 1:500 dilution for 60 min at RT, and detected using a mouse on rat HRP detection kit (Biocare MRT621H) and diaminobenzidine tetrahydrochloride chromogene (Biocare, BDB2004H). Stained tissue sections were evaluated by light microscopy for glomerular crescent formation (per 100 glomeruli) and to determine the number of ED-1 positive cells per glomerulus (a total of 25 glomeruli were evaluated per animal).
Toxicology/toxicokinetics
Rats (HsdHAN:WIST, Harlan, Bicester, UK) were injected IV over a one month period with weekly doses of BaxB01 at dose levels of 25, 100, or 250 mg/kg (n = 10/sex/group). At regular intervals, animals were observed for activity, physical condition, body weight, food consumption, morbidity and mortality. At the end of the study, hematology, coagulation, blood chemistry, ophthalmology and urinalysis was performed. The following indicators of kidney function were analyzed: sodium, potassium, glucose, calcium, urea, inorganic phosphorus, chloride, and creatinine. Urine samples were collected overnight from all toxicity animals in week 5 (and from all recovery animals in week 9). Food and water were removed during urine collection. The following urinalysis parameters were determined: volume specific gravity, glucose, bilirubin, color, pH, ketones, blood, turbidity, protein, urobilinogen, and microscopy of sediment. The scheduled necropsies were performed after an overnight period without food and after an intraperitoneal overdose of sodium pentobarbitone. A full tissue panel was prepared in the appropriate fixatives and examined microscopically.
Blood samples for toxicokinetics from satellite groups were collected from the lateral caudal vein into tubes containing 0.1 ml 3.8% citrate pre-dose and 0.25, 2, 8, 48, 72, and 168 h after the first and fifth dose.
Statistical analysis
Samples from four NTS-treated rats showed no crescent formation and no meaningful increase in urine total protein, albumin, or TNF-α levels. These animals were considered non-responders to NTS treatment and were excluded from data presentation and statistical evaluation. Statistical analysis of total protein, albumin, and TNF-alpha was performed using R version 3.2.2 (R Development Core Team, 2016) . The level of statistical significance was set to 5%. No adjustment for multiplicity was applied.
Proof of concept
Testing for a more favorable outcome with a higher dose was done by non-parametric Jonckheere-Terpstra test (Ting, 2006) as implemented in the R package clinfun (Seshan, 2014) . The null hypothesis of no dose-effect was tested against the one-sided alternative of lower measurements with a higher dose, assuming a monotone dose-response relationship.
Identification of effective doses compared with buffer
Effective dose groups were identified by many-to-one comparisons for each dose group with buffer. Differences were assessed by ratios and corresponding two-sided 95% confidence intervals calculated according to Fieller's theorem (1954) . Two-sided P-values are also presented.
Dose response modeling
Dose response relationship was investigated using the MCPMod (Multiple Comparison Procedure -Modeling) procedure as implemented in R package DoseFinding (Bornkamp et al., 2016) . Candidate models included linear, linear in log-dose (linlog), E-max, logistic, sigmoid E-max, and beta models as described (Ting, 2006) . The model with the largest t-statistic was selected and used to calculate ED 50 and ED 90 values, which represent the doses that achieve 50% and 90% of the maximum effect at the highest dose relative to buffer.
Toxicology
Clinical chemistry, urinalysis, and seminology variables were evaluated using one-way analysis of variance (ANOVA), separately for each sex. Levene's test was used to assess the equality of variances among the groups. Where no evidence of heterogeneity (P ≥ 0.01) was shown, Dunnett's test was used to make pairwise comparisons with control. Where there was evidence of heterogeneity (P < 0.01), the data were analyzed using the non-parametric methods Kruskal-Wallis ANOVA, Terpstra-Jonckheere test for a dose-related trend, and Wilcoxon rank sum test for pairwise comparisons.
Results
BAXB01 binds rat oxMIF with high affinity and inhibits migration of rat monocytes in vitro
Rat MIF protein is ∼90% homologous with human MIF (Thiele et al., 2015) . Immobilized BaxB01 binds to rat oxMIF, generated by treating MIF with Proclin300, with high affinity (K D 5.6 ± 1.1 nM), which was only slightly lower than that determined in parallel with human protein (K D 1.7 ± 0.3 nM).
BaxB01 dose dependently inhibited cell migration (IC 50 10.5 ± 2 nM) ( Fig. 1 ) while control antibody tested in the same dose range showed no effect (data not shown).
Comparative pharmacokinetics of BaxB01 in healthy and diseased Wistar Kyoto (WKY) rats
Intravenous single-dose administration of BaxB01 (50 mg/kg) to healthy rats showed an expected low clearance (CL; 0.557 ml/h/kg) and long terminal half-life (214 h) for a mAb (Table 1) . Treatment of rats with NTS-induced GN resulted in comparable recovery and initial half-life (8 h) and the same volume of distribution (Vss; 147-149 ml/ kg), but higher plasma CL (1.287 ml/h/kg) and markedly lower terminal half-life (102.96 h) than in healthy animals, with mean residence time (MRT) decreasing from about 11 days to 5 days, accordingly. Plasma exposure to BaxB01 over time curve (AUC 0-14 days ) in healthy rats was thus approximately double that in diseased rats. No BaxB01 anti-drug antibodies or neutralizing antibodies were detected in samples from either healthy or diseased rats (data not shown).
Dose ranging and pharmacokinetics in a model of proliferative nephritis in WKY rats
The calculated PK parameters (Table 2) indicated that BaxB01 plasma exposures (the ratios of dose normalized AUC 0-96 h ) were approximately dose proportional for doses up to 20 mg/kg. The increase in exposure at the highest dose level was slightly less than dose proportional (vs. 1 mg/kg) on day 4. Plasma exposure (AUC 0-96 h ) remained essentially unchanged or increased slightly after administration of a second dose on day 11 days, with exposure ratios (vs. single dose) ranging from approximately 1 to 1.4 (Table 2) .
3.4. Model of proliferative GN in WKY rats: baseline characteristics and disease progression NTS induced nephritis-related symptoms characterized by profoundly increased levels of urinary indicators of kidney inflammation and disease progression. No overt differences were observed in total urine volume, among groups or at different time points. While TNF-α was not detectable in pretreatment urine samples from controls, levels increased after NTS administration by day 4 (8.66 ± 2.44 pg/24 h) and peaked (213.05 ± 19.86 pg/24 h) on day 8 (mean ± S.E.M.). Signs of nephrotoxicity and disease progression were monitored by assessing proteinuria/albuminuria. Pretreatment urinary protein levels in controls (15.4 ± 1.0 mg/24 h) rose to 160.09 ± 9.82 mg/24 h on day 8 and 262.1 ± 14.97 mg/24 h on day 15. Similarly, pretreatment urinary albumin levels in controls (0.25 ± 0.02 mg/24 h) rose to 77.93 ± 8.42 mg/24 h on day 8 and 126.11 ± 5.42 mg/24 h on day 15. No significant differences in proteinuria/albuminuria were observed among groups on study day 4, and no significant differences in proteinuria were detected between the control groups at any time point during the study (Suppl . Table 1 ). Therefore, all group comparisons below were made with the buffer control group unless otherwise indicated.
Disease-modifying activity by single-dose administration in a model of proliferative GN in WKY rats
A single IV administration of BaxB01 produced a dose-related attenuation of the increase in urinary TNF-α (Fig. 2) . TNF-α levels (33.69 ± 5.86 pg/24 h; P < 0.001) were lowest in the high-dose group (40 mg/kg), and dropped to 15.8% of control values. This inflammation marker also significantly dropped to 30.4% of control values in the 20 mg/kg group (64.78 ± 9.7 pg/24 h; P < 0.001). Lower but statistically significant decreases in TNF-α were observed in all other dose groups including the lowest (1 mg/kg; 130.6 ± 15.74 mg/24 h; P = 0.0011). Trend analysis across dose groups on day 8 indicates that the TNF-α suppressive effect was statistically superior (P < 0.0001, Jonckheere-Terpstra test) with a higher dose. Interestingly, this effect was not sustained on day 11 when mean plasma BaxB01 concentration decreased below 50 µg/ml. A decrease in mean TNF-α levels to 67.8% of control values was demonstrated in the 40 mg/kg group; however, trend analysis across dose groups showed no effect (P = 0.1054, Jonckheere-Terpstra test).
Next, an association between TNF-α levels with attenuated disease progression and improved kidney function was evaluated by analyzing proteinuria and albuminuria in the same 24-h urine samples. The highest protein levels were measured in control samples, with proteinuria evident on day 8 (160.09 ± 9.82 mg/24 h) and more pronounced on day 11 (230.22 ± 11.15 mg/24 h), indicating established or progressing nephropathy within the studied timeframe (Fig. 3A) . Pairwise comparisons of treatment groups (vs. control) suggest that 10 mg/kg was the lowest dose level to attenuate proteinuria on day 8 (118.08 ± 6.96 mg/24 h; P < 0.001). This minimal effect level correlated with a mean plasma exposure AUC 0-96 h of 4367 µg/ml h ( Table 2 ). As shown in Fig. 3A , alleviation of proteinuria was doserelated, and most effective at the highest dose (40 mg/kg: 87.5 ± 7.08 mg/24 h; P < 0.001), reducing urinary protein content to 54.5% of controls. Trend analysis across treatment groups confirmed decreased proteinuria on day 8, with a superior response at higher dose levels (P < 0.0001, Jonckheere-Terpstra test). Attenuation of proteinuria to 47.1% of controls (P < 0.001) was sustained on day 11 (168 h, W. Höllriegl et al. European Journal of Pharmacology 820 (2018) 206-216 40 mg/kg) (Fig. 3A) . Albuminuria data consistently confirmed that BaxB01 has a doserelated disease-modifying effect (Fig. 3B) . Treatment with BaxB01 suppressed development of albuminuria in a dose-related manner, with the highest dose level showing the greatest effect (35.55 ± 3.7 mg/ 24 h; P < 0.001) at 45.6% of controls on day 8 (96 h) and to 53.0% of controls (P < 0.001) on day 11 (168 h). Trend analyses across treatment groups confirmed that a superior response was effected at higher dose levels (P < 0.0001, Jonckheere-Terpstra test).
Sustained disease-modifying activity after repeated-dose administration BaxB01
Following the second dose BaxB01 plasma exposure (AUC 0-96 h ) remained essentially unchanged or increased slightly up to 1.4-fold (Table 2) . TNF-α levels in the control group appeared to have temporarily decreased from day 8 to day 15 (87.37 ± 14.0 pg/24 h), but remained profoundly higher than pretreatment levels. Urinary TNF-α values were significantly lower in all BaxB01 treatment groups (P < 0.001 vs. buffer control group) on day 15. The greatest effect occurred in the 40 mg/kg dose group (14.7% of control), thus reestablishing the anti-inflammatory effect observed on day 8. Total urinary protein increased in the control group from day 8 to day 15 (262.1 ± 15.0 mg/24 h), with a 63.7% increase in total protein during this period. In contrast, the increase in total protein during this time frame was markedly lower in the 20 and 40 mg/kg groups (16% and 11% of controls), with the lowest levels observed on day 15 in the latter group (96.9 ± 15.6 mg/24 h). Overall, the attenuating effect of BaxB01 on disease progression was sustained in WKY rats with established renal disease.
Pharmacodynamic modeling of surrogate endpoints of disease progression and disease modification in WKY rats
To further investigate the posology of BaxB01 in the treatment of GN, data from the single-dose studies were used to delineate pharmacologically effective doses and their associated plasma exposure levels. The above described PK data and directly associated pharmacodynamic data within one week after administration of BaxB01 (i.e. TNF-α levels on day 8 and proteinuria on day 11) were applied to build predictive PD models ( Fig. 4A and B) .
First, the decreases in TNF-α were used as an early marker for antiinflammatory activity, and a PD model developed which allowed calculation of a dose that induces 90% pharmacodynamic activity (ED 90 ) on TNF-α levels (compared with the buffer control group). The modelcalculated ED 50 (3.62 mg/kg) and ED 90 (25.1 mg/kg) were associated with a plasma exposure (AUC 0-96 h ) of 1350 and 9360 µg/ml h, respectively (Fig. 4A) . Next, a PD model was developed to describe alleviation of proteinuria as a marker for disease modification at one week (168 h) after the first dose (Fig. 4B ). The PD model for attenuation of proteinuria determined ED 50 and ED 90 associated plasma exposures (AUC 0-168 h ) of 4880 and 10,800 µg/ml h. Both models are in good agreement in predicting the ED 90 for BaxB01 and the associated exposure levels needed to achieve a near maximum PD effect.
BaxB01 reduced cellular inflammatory response correlates with preserving kidney histology and reducing glomerular crescent formation in diseased WKY rats
The same study animals (n = 6-8/group) were examined histopathologically to determine the numbers of inflammatory cells and the fraction of crescents per total glomeruli on study days 8 and 15. As expected, CD68/ED1-positive (ED1+) cells were detected in all study groups, and the highest number of ED1+ cells was determined in the buffer control group on day 15 (28.8 ± 1.8 cells per glomeruli, mean ± S.E.M.) and treatment with BaxB01 at 40 mg/kg resulted in fewer ED1+ cells (19.7 ± 1.1 cells). Lower dose levels resulted in smaller effects, but were still different from buffer control on day 15 (10 mg/kg: 24.0 ± 0.8 cells, P < 0.05; 20 mg/kg: 22.5 ± 1.2 cells, P < 0.001). Trend analyses across treatment groups confirmed a reduction in the numbers of ED1+ cells /glomerulus, with higher dose levels effecting a superior response (P < 0.0001, Jonckheere-Terpstra test). In addition, PD modeling of the cellular data indicated an ED 90 of 25.1 mg/kg for BaxB01, which is consistent with the doses predicted to effectively suppress the other disease parameters discussed above.
No significant group differences in the fraction of glomerular crescents were observed on day 8, and the fraction increased numerically in all groups by day 15 (Suppl. Table 1 ). Crescent formation was detected in all study groups, with the highest fraction in the buffer (87 ± 2 per 100 glomeruli; mean ± S.E.M.) and IgG control (75 ± 3) groups on day 15. BaxB01-treated groups (20 and 40 mg/kg) showed lower fractions of crescentic glomeruli (58 ± 3 and 59 ± 4, respectively) compared (area under the curve from 0 to day 14), AUC 0-∞ (area under the curve from 0 to infinity). (13, 193) Values are geometric means and values in parentheses are the two-sided 95% confidence intervals. Exposure levels after treatment with a control IgG1 antibody (40 mg/kg) in the same study were 429 μg/ml (C max ) and 17,614 μg/ml h (AUC 0-96 h ) after the first dose, and 15,967 μg/ml h (AUC 0-96 h ) after the second weekly dose.
with the control groups (P < 0.01 -0.0001). PD modeling of the histopathology data indicated an ED 90 of 25.1 mg/kg for BaxB01, which is in excellent agreement with the doses predicted to effectively suppress monocyte/macrophage invasion of glomeruli. To mechanistically explore BaxB01's pharmacology, a possible correlation with inflammatory and pathology endpoints was examined. To this end, paired data collected from individual animals (day 15) were used to elucidate a relationship between glomeruli-associated ED1+ cell numbers with the fraction of crescentic glomeruli. Fig. 5 shows the results of correlation analyses for individual rats administered either buffer (0 mg/kg) or BaxB01 (40 mg/kg). The control group showed no correlation between the two parameters ( Fig. 5A ; r = 0.12; P = 0.387) whereas BaxB01 demonstrated a strong correlation between the antiinflammatory response (lower ED-1+ cells) with a lower fraction of crescentic glomeruli ( Fig. 5B ; r = 0.79; P = 0.010).
BaxB01 is well tolerated and does not induce signs of toxicity in rats
Having determined a minimum anticipated biological effect level and effective dose range within a model of kidney disease, the safety of BaxB01 was evaluated. Five weekly doses were administered IV to female and male rats at increasing dose levels (25, 100, and 250 mg/kg). Mean peak plasma concentrations (C max ) up to 0.63, 1.95, and 5.02 mg/ ml; and corresponding weekly exposures (AUC 0-168 h ) up to 41.5, 87.5, and 164.3 mg/ml h, respectively, were achieved. Thus, exposures were up to 15.2-fold the pharmacologically active ED 90 (AUC 0-168 h 10.8 mg/ ml h) alleviating proteinuria in rats.
Values for clinical chemistry and kidney function parameters are shown in Table 3 . No treatment-related adverse effects on kidneys were observed. At the end of treatment, calcium increased slightly in females dosed with 100 or 250 mg/kg/week, but not in males, compared with concurrent controls. Glucose increased slightly and creatinine decreased slightly in males dosed with 100 or 250 mg/kg/week, but not in females, compared with controls. Globulin and total protein increased slightly in females that received 250 mg/kg compared with controls; however, the mean value for control females was slightly lower than the historical reference range, and again the groups mean value for females was comparable to values for males. No group differences in urine volume or specific gravity were detected, and no signs of toxicity observed in urine pH, protein, or glucose collected as non-numerical values. Overall, despite some statistical differences, all parameters remained well within the normal physiological range. Histopathological assessment of the kidney and other organs (data not shown) revealed no findings related to treatment with BaxB01. In total, the data indicate that the minor differences observed were not considered harmful supporting a No Observed Adverse Effect Level of ≥ 250 mg/kg/week.
Discussion
Levels of circulating and renal MIF are higher in patients with lupus and non-lupus proliferative GN, and correlate with leukocyte infiltration, tissue damage and impairment of renal function (Lan et al., 2000; Foote et al., 2004) . MIF is constitutively expressed in normal kidney tubular epithelial cells and some glomerular visceral and parietal Fig. 2 . Single-dose treatment with BaxB01 shows anti-inflammatory effects and attenuates urinary TNF-alpha increases in NTS-treated, diseased WKY rats. Group analyses of 24 h urine samples (n = 8-16/group) at 96 h after administration of BaxB01. One-sided Jonckheere-Terpstra test showed statistically lower TNF-alpha measurements with a higher dose (P < 0.001). (Buffer-treated control group [0 mg/kg].) Boxplots: The lower edge of the box represents the 25th percentile (or 1st quartile), the upper edge of the box represents the 75th percentile (or 3rd quartile), and the line within the lower edge and the upper edge of the box indicates the median. The distance from the lower edge to the upper edge of the box represents the inter-quartile range (IQR). A whisker is drawn above the 75th percentile to the largest data value that is less or equal to the value that is 1.5*IQR above the 75th percentile. A whisker is drawn below the 25th percentile to the smallest data value that is less or equal to the value that is 1.5*IQR below the 25th percentile. The cross represents the arithmetic mean. Individual measurements were added to the boxplots, where the exact horizontal position of plotting symbols was randomly determined. Ratios of individual values versus buffer control treated group means are indicated for each treatment group with 95% confidence intervals and P-values respectively. Fig. 3 . Single-dose administration of BaxB01 to NTS-treated WKY rats attenuates disease indicators (proteinuria). Analysis of 24-h urine samples (n = 8-16/group) for urinary total protein (A) and urinary albumin (B) excretion at 96 and 168 h, respectively. One-sided Jonckheere-Terpstra test showed statistically lower values with a higher dose (P < 0.001) for proteinuria and albuminuria at both time points. Ratios of individual values vs. buffer control treated group means are indicated for each treatment group with confidence intervals and pvalues for each endpoint at 96 and 168 h. W. Höllriegl et al. European Journal of Pharmacology 820 (2018) 206-216 epithelial cells. Kidney cells show marked de novo expression of MIF during development of rat anti-GBM nephritis, including endothelium and glomerular and tubular epithelial cells, which correlates with macrophage accumulation within the glomerulus and tubulointerstitium (Lan et al., 1996; Lang et al., 2015) . Upregulation of MIF expression by parietal epithelial cells is associated with macrophage accumulation within Bowman's space and crescent formation; however, MIF is also expressed by macrophages, T cells, and fibroblast-like cells within renal lesions (Lan et al., 1997; Lang et al., 2015; Bruchfeld et al., 2016) . A recent report studying GN in mice further suggests that MIF and its receptor complex CD74/CD44 mediate glomerular injury and are crucially involved in the pathologic proliferation of glomerular cells (Djudjaj et al., 2016) . Thiele et al. (2015) previously described that MIF occurs in two immunologically distinct conformational isoforms, and identified oxMIF as the disease-related isoform predominantly expressed in patients with inflammatory diseases (Thiele et al., 2015) and in cancer patients (Schinagl et al., 2016) . As BaxB01 specifically binds oxMIF (Thiele et al., 2015) , we investigated the antibody's PK and minimally effective dose levels, and defined the exposures associated with optimal pharmacological activity.
In vitro data showed high-affinity antibody binding to rat oxMIF and inhibitory activity on rat monocyte/macrophage cell migration in the low nanomolar range, corroborating functional activity in this species (Kerschbaumer et al., 2012) .
Comparative PK data for BaxB01 generated in healthy and diseased rats indicate discordant plasma exposure during progressive inflammatory kidney disease. CL, C max , MRT, and terminal half-lives were not equivalent, and plasma exposure (AUC 0-day 14 ) was twice as high in healthy rats than in diseased rats. The Vdss in healthy and diseased rats indicates that the distribution of BaxB01 is not limited to the plasma compartment (Davis and Morris, 1993) . The lower exposure in diseased animals may be due to diminished glomerular filtration and proteinuria. Increases in urinary oxMIF were previously shown in the rat model of GN and in LN patients with acute renal flares (Thiele et al., 2015) . Another mechanistic explanation for the reduced exposure could be target-mediated drug disposition via sequestration of BaxB01 in the inflamed tissue compartment, as previously described for other mAbs targeting cell surface associated targets (Dostalek et al., 2013) . However, the interpretation of BaxB01 distribution awaits confirmation by more focused investigation.
To assess PK/PD relationships, the current study investigated the PK and disease-modifying activity in the same animals. BaxB01 exposure was dose-related and thus allowed us to define minimally effective doses and calculate exposures that attenuate disease progression. The data indicated a highly dose-related amelioration of inflammatory activity (TNF-α), likely also contributing directly to reduced progression of disease and improved kidney function as demonstrated by ameliorated proteinuria and albuminuria in BaxB01 treatment groups. While not tested in the current study, this interpretation is consistent with neutralization of TNF-α effectively preventing glomerular inflammation and crescent formation in WKY rats (Karkar et al., 2001; Khan et al., 2005) . The modeled ED 90 and associated exposure levels for the various PD readouts (urinary TNF-α, proteinuria, albuminuria) are consistent with the exposure driven efficacy of BaxB01. Slightly lower doses/exposures may be required for initial suppression of TNF-α levels than for disease modification. This inference is supported by previous studies demonstrating MIF-induced stimulation of TNF-α secretion by macrophages, suggesting that these two cytokines act together in a pro-inflammatory loop (Calandra et al., 1994) . However, the anti-inflammatory mechanism was not consistently engaged by BaxB01 and appeared to resolve at the end of the treatment cycle (168 h post-dose) when TNF-α levels were temporarily not significantly suppressed, while the blockade of disease progression (proteinuria) was maintained. The corresponding plasma exposure (C trough 168 h) was below 50 µg/ml in all dose groups, indicating that minimal exposure levels are required to sustain BaxB01 anti-inflammatory activity in the rat. Consistent with this notion, administration of a second weekly dose of BaxB01 resulted in a significant decrease in TNF-α (vs. control), corroborating the causal exposure-related anti-inflammatory mechanism. The lowest dose to affect a clinically relevant parameter (proteinuria) was 10 mg/kg, as this dose significantly reduced urine total protein compared with both control groups within one week of dosing, while PD modeling using actual exposure data allowed estimation of a near optimal (ED 90 ) proteinuria-alleviating exposure of 10.8 mg/ml h. In line with these results, a previous study reported partial reversal of disease parameters by daily administration of a murine anti-MIF antibody to Sprague Dawley rats (Yang et al., 1998) ; however, the study tested only one dose level and actual exposure values were not reported.
On the cellular and tissue level, dose-related decreases in ED1+ cell number and preservation of healthy glomerular histology suggest altered immune cell function and/or migration by BaxB01's mechanism of action. This hypothesis is supported by several lines of evidence. 
Table 3
Clinical chemistry and urinalysis data collected in male (m) and female (f) rats after administration of five weekly intravenous BaxB01doses of 250 mg/kg.
First, PD modeling indicates strikingly similar near optimal dose levels (25.1 mg/kg) to alleviate cellular inflammation as well as reduce crescent formation. Second, correlation analysis in individual animals treated with BaxB01 clearly defines a relationship of decreased glomerular monocyte/macrophage cell numbers (ED1+ cells) with ameliorated histopathology. Overall, these findings indicate mitigated inflammatory insult together with reduced kidney pathology, which is in good agreement with the decreases observed in renal leukocyte infiltration by MIF inhibition (Yang et al., 1998) and the effectiveness of anti-CD8 mAb therapy on reducing both CD8 and ED1 positive cell counts in the WKY rat (Reynolds et al., 2002) . The beneficial effects of anti-oxMIF treatment by BaxB01 were linked to a reduction of Th1-based inflammatory cytokines in models of inflammation previously (Thiele et. al, 2015) , while a role for MIF in the differentiation of inflammatory Th17 cells has also been reported (Stojanović et al., 2009) . Together this opens the possibility that anti-MIF treatments mechanistically also affect the instigating role of Th17 and Th1 cells in the NTSinduced model of GN (Kurts et al., 2013; Artinger et al., 2017) . Selective BaxB01 binding characteristics for an oxidized immunologically distinct MIF variant (Thiele et al., 2015) may mitigate risks inherent to total MIF binding, and conceptually evade an antigen sink effect by the abundantly expressed cytokine. Safety is a critical attribute for any novel therapeutic and especially in the treatment of kidney disease where new therapeutic agents are likely administered together with other immunosuppressant therapy in clinical trials (Houssiau, 2014) . Safety assessment in rat included renal function by clinical chemistry parameters, urinalysis and macroscopic and histopathological examination as markers of glomerular and tubular function, and as measures of renal toxicity. Administration of BaxB01 to rats was well-tolerated at dose levels at least 25-fold the lowest dose level to effectively reduce total urinary protein (10 mg/kg) in the diseased rat, while the calculated therapeutic index based on near-optimal exposure (ED 90 ) to attenuate proteinuria was at least 15-fold.
This study and our interpretation thereof have some technical limitations. While the preclinical model does not cover all aspects of spontaneous nephritis, it is an excellent tool for exploring clinical therapeutics (Fu et al., 2007) . Treatment with BaxB01 significantly alleviated disease manifestation and disease progression, but did not prevent or reverse tissue injury, a high aspiration for a clinical outcome measurement. Besides the clear exposure driven pharmacologic alleviation of TNF-α and resident macrophages associated with glomeruli, the study design did not exclude other possible BaxB01-mediated cellular or endocrine activity.
Conclusion
In conclusion, the data described define therapeutically relevant exposure levels correlated mechanistically with disease-modifying activity, while toxicological evaluation in this species suggests a large proposed therapeutic index. Together, these findings provide preclinical evidence for achieving safe and effective exposures of a MIF isoform-directed therapeutic in the potential treatment of disease with nephritis-associated sequelae.
